Assertio (ASRT)
(Delayed Data from NSDQ)
$1.01 USD
+0.09 (9.64%)
Updated May 2, 2024 04:00 PM ET
After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Assertio Holdings, Inc. [ASRT]
Reports for Purchase
Showing records 41 - 60 ( 114 total )
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
3Q:22 Results Solid As ASRT Benefits From Strong Product Line Advance And Greater Operating Efficiencies
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Sympazan Acquistion Could Drive Valuation Expansion
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Better 3Q:22 Results Year-Over-Year As ASRT Benefits From Improved Top Line
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Contend Stock Pullback Overdone Following Proposed Convertible Notes Offering That Addresses Debt Maturity And Provides Increased Cash Liquidity
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
2Q22 Recap - Indocin Near-Term Driver; M&A Long-Term
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
2Q:22 Results Solid As ASRT Benefits From Strong Line Advance And Greater Operating Efficiencies
Provider: SIDOTI CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Better 2Q:22 Results Year-Over-Year As ASRT Benefits From Improved Top Line
Provider: SIDOTI CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Initiate Coverage Of Assertio Holdings, Inc. With a $6 Price Target And Moderately Risky Rating
Provider: SIDOTI CSR
Analyst: Research Department